Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism
Open Access
- 1 January 2018
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 2 (1) , 69-76
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim Pharma GmbH & Co. KG
This publication has 39 references indexed in Scilit:
- The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) StudyCirculation, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Antithrombotic Therapy in Neonates and ChildrenChest, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in childrenJournal of Thrombosis and Haemostasis, 2011
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage – from theory to practiceCritical Care, 2009
- Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and childrenBritish Journal of Pharmacology, 2008